Skip to main content
. 2021 Jan 15;11:592304. doi: 10.3389/fneur.2020.592304

Table 4.

Adverse events in 70 patients treated with ocrelizumab.

Adverse event n (%)
Any adverse event 37 (53%)
Infusion-related reactions* 30 (43%)
 Mild 14 (20%)
 Moderate 16 (23%)
 Severe 0
Infections 9 (13%)
 Urinary tract infections 5
 Pneumonia 1
 Cellulitis 1
 Gastroenteritis 1
 Dental phlegmon 1
Others 2 (3%)
 Alopecia areata 1
 Biliary colic 1
*

Infusion-related reactions included pruritus, sore throat, rash, flushing, urticaria, erythema, headache, irritability and myalgias.